Sarah K. Tasian, MD, University of Pennsylvania School of Medicine and Abramson Cancer Center, Philadelphia, PA, gives an overview of Phase I clinical trials of chimeric antigen receptor (CAR) T-cells for leukemia at AACR 2021. Dr Tasian discusses the use of CD33-targeted CAR T-cells for the treatment of acute myeloid leukemia (AML) in children, adolescents and young adults. Dr Tasian also outlines preclinical development of FLT3-directed CAR T-cells for FLT3 mutant AML and KMT2a-rearranged acute lymphoblastic leukemia (ALL), and a first-in-human trial of thymic stromal lymphopoietin receptor (TSLPR) CAR T-cells for CRLF2-rearranged Philadelphia chromosome-like ALL. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Sarah K. Tasian, MD, has received research funding from Incyte Corporation, and has participated in scientific advisory boards for Kura Oncology and Aleta Biotherapeutics.